The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Luke Halpern
Advertisement
Articles by Luke Halpern
There’s a balance required to manage both the symptoms of myelofibrosis through treatment and the side effects caused by the drugs, explained Firas El Chaer, MD, of the University of Virginia School of Medicine.
In addition to new treatments over the past few years changing the landscape for patients, additional treatments being evaluated are looking at new mechanisms of action, said Firas El Chaer, MD, of University of Virginia School of Medicine.
Experts discussed the great advances and innovations they’ve seen this year in acute myeloid leukemia (AML) and multiple myeloma.
Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among Black patients compared with clinical trials.
By reducing cytokine release syndrome and neurotoxicity, prophylactic tocilizumab could facilitate safe outpatient administration of bispecifics to treat multiple myeloma (MM), explained Robert Rifkin, MD.
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce toxicity, according to Amir Ali, PharmD, BCOP.
The SEQUOIA study's 5-year follow-up confirms zanubrutinib's safety profile and low cardiovascular events in treatment-naive chronic lymphocytic leukemia, according to Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center.
Severity of a COVID-19 illness could be determined by examining autoantibodies in the nasal cavity, allowing more personalized treatment protocols.
The treatment showed effectiveness in achieving local control of acute myeloid leukemia (AML) that developed in the eyes of a pediatric patient.
Although an aerobic cooldown indeed lowers blood glucose levels in adults with type 1 diabetes after fasted exercise, by itself, the impact it has on hyperglycemia is insignificant.
Hemoglobin levels, transfusion independence, and low serum erythropoietin levels were all deemed to have a statistically significant relationship with erythropoiesis-stimulating agent (ESA) response.
Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials.